CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
3.892 EUR
+0.01 (+0.36%)
Overall 5CV gets a fundamental rating of 4 out of 10. We evaluated 5CV against 86 industry peers in the Biotechnology industry. 5CV has an average financial health and profitability rating. 5CV has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- 5CV had negative earnings in the past year.
- In the past year 5CV has reported a negative cash flow from operations.
- In the past 5 years 5CV reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
- 5CV has a Return On Assets of 11.31%. This is amongst the best in the industry. 5CV outperforms 84.34% of its industry peers.
- 5CV's Return On Equity of 14.79% is amongst the best of the industry. 5CV outperforms 84.34% of its industry peers.
- With an excellent Return On Invested Capital value of 14.12%, 5CV belongs to the best of the industry, outperforming 87.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 182.11%, 5CV belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
- With an excellent Operating Margin value of 212.01%, 5CV belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 93.01%, 5CV belongs to the top of the industry, outperforming 86.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 5CV is creating value.
- 5CV has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for 5CV has been increased compared to 5 years ago.
- The debt/assets ratio for 5CV has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 4.17 indicates that 5CV is not in any danger for bankruptcy at the moment.
- The Altman-Z score of 5CV (4.17) is better than 73.49% of its industry peers.
- A Debt/Equity ratio of 0.03 indicates that 5CV is not too dependend on debt financing.
- 5CV has a better Debt to Equity ratio (0.03) than 69.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.17 |
ROIC/WACC1.96
WACC7.19%
2.3 Liquidity
- 5CV has a Current Ratio of 3.70. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
- 5CV has a Current ratio of 3.70. This is in the better half of the industry: 5CV outperforms 69.88% of its industry peers.
- A Quick Ratio of 3.69 indicates that 5CV has no problem at all paying its short term obligations.
- 5CV has a better Quick ratio (3.69) than 73.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
- 5CV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -247.92%.
- 5CV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
- Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
- The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
- The Revenue is expected to decrease by -11.14% on average over the next years. This is quite bad
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- 5CV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year 5CV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 96.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.92 |
4.3 Compensation for Growth
- 5CV's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
- 5CV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
What is the valuation status of CUREVAC NV (5CV.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.